介入治疗联合CIK细胞疗法治疗肝癌的临床观察-论文.pdf

《介入治疗联合CIK细胞疗法治疗肝癌的临床观察-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、世界最新医学信息文摘2013年第13卷第17期121·临床研究·介入治疗联合CIK细胞疗法治疗肝癌的临床观察赵莉娟，白中红，许软成，王仲倩(解放军91中心医院肿瘤科，河南焦作454003)摘要：目的观察肝动脉栓塞化疗联合细胞因子诱导的杀伤细胞(CIK)疗法治疗原发性肝癌的临床疗效。方法对2008年3月至2009年5月接受肝动脉栓塞化疗联合体外培养CIK细胞14d后分次回输疗法的23例原发性肝癌患者(治疗组)与单纯肝动脉栓塞化疗2l例患者(对照组)比较，观察患者治疗前后瘤体大小、免疫组化、临床症状、生活质量、卡氏评分、生存期等的变化。结果治

2、疗组与对照组治疗前后cD3+、CD4+、CD4+／CD8+、NK有统计学意见(尸

3、3IntervenfionaltreatmentcombinedCIKcelltherapytreatinglivercancerclinicalobservationZhaoLi=iuan，BaiZhong．hong，XuRuan-cheng，W_angZhong-qian(DepartmentofMedicalOncology,People'sLiberationArmy91CentralHospitaldiaozuo，454003,China)一一——ABSTRACT：ObieetiveObservethehepaticartery

4、embolizationchemotherapycombinedcytokine—inducedkillercells(CIK)theclinicalcurativeefrectofthetreatmentofprimarylivercancer．MethodsInMarch2008tomayaccepthepaticarteryembolizationcombinedchemotherapyinvitrocultureCIKcellsafter14dtimebacktolosepointsOfthe23casesofprimaryliv

5、ercancertherapypatients(treatmentgroup)andsimplehepaticarteryembolizationchemotherapy21patients(controlgroup)comparison，Changesintumorsizebeforeandaftertheobservationofpatients，immunohistochemistry,clinicalsymptoms，qualityOf1ife，Kamofskyperformancestatus，survivaltime，etc．

6、ResultstreatmentgroupandcontrolgroupbeforeandaftertreatmentlevelsofCD3+andCD4+，CD4+／CD8+andNKstatisticalviews(P<0．05)，aftertreatment，theclinicalsymptomsthanbeforetreatmentwereobviouslyimproved，thediferencewasstatisticallysignificant(尸

7、seratewas82．6％，thetreatmentgroupandcontrolgroupmediansurvivalrespectivelyfor22months，l1months，thetreatmentgroupsurialobvious1ongerthanincontrolgroup<0．05)．conelusionHepaticarteryembolizationcombinedchemotherapyCIKeelltherapyispurerhepaticageryembolizationchemotherapymayim

8、provetheprimarylivercancerpatientsofthelong-termsurvival，delaylivercancerrecurrence．KEYWORDS：Hep